Perspective Therapeutics
CATX

$13.23

1.78%

Market Cap: $892M

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

30% more capital invested

Capital invested by funds: $297M [Q1] → $385M (+$88.1M) [Q2]

7.12% more ownership

Funds ownership: 50.21% [Q1] → 57.33% (+7.12%) [Q2]

0% more funds holding

Funds holding: 104 [Q1] → 104 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 51

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

79% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 43

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

28%

upside

Avg. target

$23

71%

upside

High target

$27

104%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Gregory Renza 52% 1-year accuracy 38 / 73 met price target	104%upside $27	Outperform Maintained	16 Aug 2024
Oppenheimer Jeff Jones 60% 1-year accuracy 18 / 30 met price target	29%upside $17	Outperform Maintained	13 Aug 2024
B of A Securities Alec Stranahan 25% 1-year accuracy 1 / 4 met price target	81%upside $24	Buy Initiated	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Zacks Investment Research

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

3 Outperforming Stocks Surpassing Even Nvidia This Year

Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.

3 Outperforming Stocks Surpassing Even Nvidia This Year

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Zacks Investment Research

Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th.

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-adjusted basis under the existing trading symbol “CATX” and new CUSIP number 46489V302.

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

See News Rankings